Skip to main content

Novel treatment for peripheral arterial disease

Objective

Peripheral Arterial Disease (PAD) is caused by the deposition of fatty material on the inner walls of peripheral arteries causing reducing perfusion and local nutrition to the muscles and skin. The condition affect 202 million people globally and is increasing at a rate of 20% per annum due to an aging population and epidemic growth of diabetes. The social costs amounts to $210 - 380 billion per annum.
Behavioural changes such as smoking cessation, healthy nutrition and exercise is recommended to reduce impact and risk. When the condition worsens, patients ability to walk and exercise is reduced. When disease progress to critical limb ischemia (unbearable pain and chronic wounds), the patients follow a trajectory towards costly vascular surgery or amputation.
FlowOx targets the gap in care with a patented, cost effective and clinically promising home treatment solution. In order to secure the successful introduction of FlowOx into the market by 2020, resources are required to fill the following gaps in innovation:1) strong clinical evidence of efficacy 2) health economic assessment 3) design for large scale manufacturing and 4) a validated commercial model Germany, UK and Scandinavia. These 4 challenges will be addressed in the FlowOx project over a 30-month period.
The Fast Track to Innovation Pilot program was selected to support a resource demanding and technically challenging stage of the product roadmap. The support enables Otivio to join forces with a medical device manufacturer, Innokas Medical, Finland, and UK based Univ. of Salford and Univ. of Bangor with extensive experience in clinical and health economic studies. The FlowOx project enables Otivio and Innokas to enter the world-wide PAD market, gaining a strong market positon with a home care device for PAD treatment and expected sales of over €220 million within 5 years of launch.

Call for proposal

H2020-FTIPilot-2016

See other projects for this call

Sub call

H2020-FTIPilot-2016-1

Coordinator

OTIVIO AS
Net EU contribution
€ 876 000,00
Address
Gaustadalleen 21
0349 Oslo
Norway

See on map

Region
Norge Oslo og Viken Oslo
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 375 428,58

Participants (3)

INNOKAS MEDICAL OY
Finland
Net EU contribution
€ 680 750,00
Address
Vihikari 10
90440 Kempele

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Manner-Suomi Pohjois- ja Itä-Suomi Pohjois-Pohjanmaa
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 291 750,00
THE UNIVERSITY OF SALFORD
United Kingdom
Net EU contribution
€ 375 000,00
Address
The Crescent 43
M5 4WT Salford

See on map

Region
North West (England) Greater Manchester Greater Manchester South West
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
BANGOR UNIVERSITY
United Kingdom
Net EU contribution
€ 148 750,00
Address
College Road
LL57 2DG Bangor

See on map

Region
Wales West Wales and The Valleys Gwynedd
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00